Goodwin + KPMG @ JPMorgan Symposium – Virtual

Our 3rd Annual Goodwin + KPMG @ JPMorgan Symposium will take place virtually due to JPMorgan’s decision to move the conference to a fully virtual experience. Our agenda is evolving and new speakers and participants are being added. If you have questions, please reach out to Martina Toponarski.

Day One: Wednesday, January 12

Register

Welcome Remarks – 10:30 AM - 10:40 AM ET

  • Mitch Bloom, Chair, Life Sciences and Partner, Goodwin
  • Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG

Europe Unleashed 

Europe Unleashed – 10:40 AM - 11:50 AM ET

Ignite Talk: The State of European Biotech – 10:40 AM - 11:00 AM ET

The Evolving European Ecosystem: A Discussion of Current Trends and Themes within the European Life Sciences Sector – 11:00 AM - 11:45 AM ET

This panel will address the challenges and dynamics of various clusters of biotech innovation in Europe with the UK being the leader as well as other strong centers such as Nordics. We will also discuss emerging clusters that are a couple of years behind the UK and Nordics but are the next places to be such as France and Germany and other continental parts of Europe.

  • Sophie McGrath, Partner, Goodwin (Moderator)
  • Jasper Bos, Ph.D., General Partner, Forbion
  • Rachel Mears, Partner, Jeito Capital
  • Søren Møller, Managing Partner, Novo Holdings

Break – 11:45 AM - 11:55 AM ET

 

Healthcare 

Healthcare – 11:55 PM - 1:40 PM ET

Ignite Talk: Hot Topics in 2022 and Beyond in the Healthcare Regulatory Environment – 11:55 PM - 12:10 PM ET

Panel: An Industry in Transformation – 12:10 PM - 12:40 PM ET

In recent years, we have seen several technology companies attempt to transform their businesses by adding healthcare components and developing products and apps that are regulated by the FDA. Conversely, we have also seen traditional medical technology companies develop products that enable data platforms that hold vast amounts of aggregated patient and prescriber data. As tech companies trend towards healthcare, and as healthcare companies move towards tech, this panel will explore what challenges these companies face in terms of competition, regulatory controls and government oversight.

  • Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG (Moderator)
  • Sarah Bobulsky, CFO of Commercial, Helix
  • Dave Cappillo, Partner, Goodwin
  • Chris Klomp, Chief Evangelist, PointClickCare

Fireside Chat – Innovation in Women’s Health and Wellbeing: Critical Legal Considerations – 12:40 PM - 1:10 PM ET

We are at a turning point in the transformation of healthcare, and technological innovation in the Women’s Health and Wellbeing sector has never been stronger. The industry is expected to reach $41 billion by 2027 and is experiencing a newfound interest in removing the barriers that stalled its growth for decades. The evolution of the industry raises important legal issues and regulatory challenges that must be overcome to propel the industry forward. This fireside chat will address why the sector is attracting more investment, the legal structures that must be shifted to facilitate this evolution, the role that technology is playing in transforming the space, and where technological innovation still needs to catch up to improve the lives of women everywhere. 

  • Delphine O’Rourke, Partner, Goodwin (Moderator)
  • Sandy Milligan, MD JD, Head of Research and Development, Organon

Panel: Privacy Guardrails for the Digital Healthcare Revolution – 1:10 PM - 1:55 PM ET

Large scale digital processing of sensitive personal data has powered technology that has brought treatment and support to countless patients. From access to mental health, nutrition guidance and medicine to patient portals and support communities, and to medical research, entrepreneurs have created technology to improve and save lives. This panel will look at the data trends and technologies that are reshaping healthcare, and how companies can handle sensitive personal data fairly and transparently, respecting privacy and data protection laws and societal expectations, as well as articulate their privacy-protective stance to patients, regulators and the society at large. Our discussion will touch on the evolving global privacy landscape, including in the United States, Europe and other parts of the world, and offer participants practical guidance on privacy compliance guardrails in health tech.

  • Boris Segalis, Partner, Goodwin (Moderator)
  • Lore Leitner, Partner, Goodwin
  • Gordon Kessler, CAO General Counsel, AiCure
  • Ashley Yesayan, Founder and CEO, OneVillage
  • Dan Ayala, Chief Information Security Officer, LabArchives
  • Orson Lucas, Principal, Advisory, Cyber Security Services, KPMG

Keynote Fireside Chat with Tony Coles – 2:00 PM - 2:45 PM ET

  • Stuart Cable, Partner, Vice Chairman, Global Chair of M+A, Goodwin (Moderator)
  • Tony Coles, M.D., CEO and Chairperson, Cerevel Therapeutics

Day Two: January 13

Register

Capital Markets

Capital Markets – 1:00 PM - 2:35 PM ET

Ignite Talk: State of Capital Markets – 1:00 PM - 1:15 PM ET

  • Jack Bannister, Managing Director, SVB Leerink

Panel – Accessing the Public Markets: Charter Your Own Course – 1:15 PM - 2:00 PM ET

This interactive life sciences capital markets panel will focus on the key steps for deciding which type of offering to pursue, best practices for preparing and executing a capital markets transaction, ways to mitigate litigation risk along the way, and what you can expect to encounter as a newly public company.

Fireside Chat: Stories from the Front – 2:00 PM - 2:35 PM ET

  • Katie Wechsler, Audit Partner, KPMG (Moderator)
  • Mike Byrnes, Chief Financial Officer, eFFECTOR
  • Jason O’Byrne, CFO, Caribou Biosciences

Innovative Strategies  

Keys to Unlocking Innovative Strategies – 2:40 PM - 4:10 PM ET

Fireside Chat: Antitrust Expansion in Life Sciences Collaborations – 2:40 PM - 3:30 PM ET

The Federal Trade Commission (FTC) and other competition agencies across the globe have increased their scrutiny of transactions in the life sciences industry. The FTC has spearheaded the formation of a Multilateral Pharmaceutical Merger Task Force to explore potentially new theories of harm and new ways to analyze the competitive effects of proposed transactions. At the same time, the industry continues to be innovative in its deal making to manage the technical, regulatory and commercial risks. This fireside chat will address the unique antitrust issues that arise when smaller innovative life sciences companies collaborate with or get acquired by big pharma, and how the new trends in antitrust scrutiny might affect such transactions. 

Fireside Chat – Approaching a New 2022: The Real Keys to Innovative Deal Making This Year – 3:30 PM - 4:10 PM ET

Over the last year, despite the ongoing challenges of the pandemic, the life sciences industry has seen some of its most innovative deals to date. This panel will highlight lessons learned from these deals, including the need to get creative, and discuss which tactics are here to stay.

  • Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG (Moderator)
  • Bonnie Anderson, Co-founder and Executive Chairwoman, Veracyte

2022 Highlights & Takeaways

Day One: Wednesday, January 12, 2022

We kicked off the Symposium with three industry-focused bursts starting with the state of the European biotech market and a panel discussing the current trends and themes within the European life sciences sector. The second burst on healthcare started with a look at the hot topics in healthcare regulatory for 2022 followed by a panel on the digital health industry transformation, a fireside chat on innovation in the expanding women’s health and wellness ecosystem and a panel on privacy trends and technologies that are reshaping healthcare. We closed the first day with a keynote fireside chat with industry luminary Tony Coles, CEO and Chairperson of Cerevel Therapeutics. 

Panel Titles: 

  • The State of European Biotech
  • The Evolving European Ecosystem: A Discussion of Current Trends and Themes within the European Life Sciences Sector
  • Hot Topics in 2022 and Beyond in the Healthcare Regulatory Environment
  • An Industry in Transformation
  • Fireside Chat – Innovation in Women’s Health and Wellbeing: Critical Legal Considerations
  • Privacy Guardrails for the Digital Healthcare Revolution
  • Keynote Fireside Chat with Tony Coles, CEO and Chairperson, Cerevel Therapeutics

View the Video:

 

Keynote Fireside Chat with Tony Coles, CEO and Chairperson, Cerevel Therapeutics

Day Two: Thursday, January 13, 2022

We kicked off the second day with an overview of the capital markets landscape from 2021 and leading into 2022. This was followed by a panel discussing the key steps for deciding which type of offering to pursue and how to chart your own course in this ever-changing market, as well as a fireside chat with two CFOs of companies that recently went public,  eFFECTOR and Caribou Biosciences. The second and final burst of the day started with a fireside chat on the antitrust expansion in life sciences collaborations.  We concluded the Symposium with a fireside chat with Bonnie Anderson, co-founder and executive chairwoman of Veracyte who showcased the keys to innovative deal making for 2022. 

Panel Titles:

  • State of Capital Markets
  • Accessing the Public Markets: Charter Your Own Course 
  • Fireside Chat: Stories from the Front
  • Fireside Chat: Antitrust Expansion in Life Sciences Collaborations 
  • Fireside Chat – Approaching a New 2022: The Real Keys to Innovative Deal Making This Year

View the Video:

Goodwin's Life Sciences Practice

Goodwin knows that succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. In this highly competitive business, you need more than the best and brightest ideas - you need a legal and strategic partner that understands the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing products line.

Goodwin can help. We know the market, the players and the science. With a full service team of highly experienced lawyers resident in key life sciences hubs, Goodwin helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle.

Click here to learn more about Goodwin's Life Sciences practice.

Case Studies

Recent News

Life Sciences Perspectives

Goodwin’s Life Sciences Perspectives Blog is a resource specifically aimed at addressing your most frequent and pressing issues and providing insights on current developments. The challenges across the life sciences industry are as abundant as the opportunities. From tightening federal regulations and market forces to revolutionary innovations, the headwinds are stiff and shifting but they are navigable. We will be tracking emerging issues and developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies. Read the Life Sciences Perspectives Blog >>
 
Life Sciences Perspectives